Illumina, Inc.
A maker of DNA sequencing and genetic analysis instruments, Illumina is one of the world's largest genomics technology companies, serving researchers and clinicians in noninvasive prenatal testing and cancer detection. Founded in 1998 in San Diego by a venture capitalist and a Tufts chemist, its name comes from the Latin word for 'light,' a nod to its fluorescence-based detection—and despite how it sounds, it has nothing to do with the Illuminati. Sequencing machines like the MiSeq decode genomes.
Granted 4.6K · Sold 2.05M
Granted 104.9K · Bought 19.7K
Granted 46.0K
Granted 27.3K
Granted 28.0K · Bought 6.1K
Granted 21.5K
Granted 5.6K
Granted 8.5K
Granted 6.4K
Granted 21.7K · Sold 3.9K
Granted 14.2K · Sold 2.9K
Granted 6.4K
Granted 6.7K
Granted 8.5K
Granted 12.9K
Granted 5.6K
Granted 6.4K
Granted 8.5K
Granted 8.8K · Bought 700
Granted 11.4K · Sold 2.0K
Granted 15.7K · Sold 2.3K
Granted 10.4K
Granted 8.5K
Sold 315
Granted 2.6K
Granted 2.1K
Granted 1.7K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Meister Keith A.Director · 78 transactions | — | 15.05M | 4.6K | — | 2.05M |
| Thaysen JacobChief Executive Officer, Director · 21 transactions | — | 109.1K | 104.9K | 19.7K | — |
| Tousi Susan HSVP, Chief Commercial Officer · 1 transaction | — | 89.3Kas of Nov 2023 | — | — | — |
| Cunningham EverettSVP, Chief Commercial Officer · 3 transactions | — | 46.6Kas of Jul 2025 | 46.0K | — | — |
| Barnard StevenSVP, Chief Technology Officer · 15 transactions | +116.7% | 41.3K | 27.3K | — | — |
| Dhingra AnkurSVP, Chief Financial Officer · 4 transactions | — | 34.3K | 28.0K | 6.1K | — |
| Pegels Kevin CarlChief of Global Operations · 10 transactions | +141.1% | 29.0K | 21.5K | — | — |
| Goswami JoydeepSVP, Chief Financial Officer · 3 transactions | +18.1% | 24.5Kas of Mar 2024 | 5.6K | — | — |
| Schiller Philip WDirector · 3 transactions | +62.3% | 22.2K | 8.5K | — | — |
| Epstein Robert SDirector · 3 transactions | +35.9% | 22.1Kas of May 2025 | 6.4K | — | — |
| Leckman PatriciaSVP, Chief People Officer · 20 transactions | — | 21.4K | 21.7K | — | 3.9K |
| Davies Scott MChief Legal Officer · 14 transactions | — | 21.0K | 14.2K | — | 2.9K |
| Arnold FrancesDirector · 3 transactions | +43.5% | 20.9Kas of May 2025 | 6.4K | — | — |
| Dadswell CharlesSVP, General Counsel · 4 transactions | +21.3% | 20.6Kas of Sep 2024 | 6.7K | — | — |
| Siegel Susan EDirector · 3 transactions | — | 20.5K | 8.5K | — | — |
| Rollins CarissaSVP, Chief Information Officer · 7 transactions | +183.9% | 18.4Kas of Apr 2025 | 12.9K | — | — |
| Reeves Kathryne GambrellSVP, Chief Marketing Officer · 3 transactions | +36.2% | 18.0Kas of Mar 2024 | 5.6K | — | — |
| Guthart Gary SDirector · 2 transactions | +64.7% | 16.4Kas of May 2025 | 6.4K | — | — |
| Dorsa CarolineDirector · 6 transactions | +51.2% | 15.8K | 8.5K | — | — |
| Gottlieb ScottDirector · 7 transactions | +184.2% | 14.8K | 8.8K | 700 | — |
| Ericksen Scott DVP, Chief Accounting Officer · 13 transactions | +81.7% | 14.4K | 11.4K | — | 2.0K |
| Wedel Christensen JakobSVP, Strategy/Corp Development · 13 transactions | — | 14.0K | 15.7K | — | 2.3K |
| Ullem Scott B.Director · 13 transactions | — | 10.9K | 10.4K | — | — |
| Richo AnnaDirector · 3 transactions | — | 8.5K | 8.5K | — | — |
| Hoyt Aimee LSVP, Chief People Officer · 2 transactions | +188.6% | 8.3Kas of Nov 2023 | — | — | 315 |
| Macmillan Stephen PDirector · 1 transaction | — | 4.1Kas of May 2024 | 2.6K | — | — |
| King David PDirector · 1 transaction | — | 2.1K | 2.1K | — | — |
| Skovronsky DanielDirector · 1 transaction | — | 1.7K | 1.7K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: -2.04M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.